What science can do



We are transforming the future of healthcare by unlocking the power of what science can do, for people, society and planet.






Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025.

Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca